UTHR Quote, Financials, Valuation and Earnings

Insmed has a net margin of 40.56% compared to United Therapeutics's net margin of -276.42%. United Therapeutics's return on equity of 19.92% beat Insmed's return on equity of -1146.32%.

United Therapeutics has a consensus price target of $377.09, signalling upside risk potential of 25.63%. On the other hand Insmed has an analysts' consensus of $113.22 which suggests that it could grow by 15.32%. Given that United Therapeutics has higher upside potential than Insmed, analysts believe United Therapeutics is more attractive than Insmed.

United Therapeutics has a beta of 0.534, which suggesting that the stock is 46.629% less volatile than S&P 500. In comparison Insmed has a beta of 0.902, suggesting its less volatile than the S&P 500 by 9.818%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

United Therapeutics quarterly revenues are $794.4M, which are larger than Insmed quarterly revenues of $92.8M. United Therapeutics's net income of $322.2M is higher than Insmed's net income of -$256.6M. Notably, United Therapeutics's price-to-earnings ratio is 11.98x while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 4.84x versus 44.35x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

Liquidia has a net margin of 40.56% compared to United Therapeutics's net margin of -1229.71%. United Therapeutics's return on equity of 19.92% beat Liquidia's return on equity of -165.38%.

United Therapeutics has a consensus price target of $377.09, signalling upside risk potential of 25.63%. On the other hand Liquidia has an analysts' consensus of $30.30 which suggests that it could grow by 115.05%. Given that Liquidia has higher upside potential than United Therapeutics, analysts believe Liquidia is more attractive than United Therapeutics.

United Therapeutics has a beta of 0.534, which suggesting that the stock is 46.629% less volatile than S&P 500. In comparison Liquidia has a beta of -0.012, suggesting its less volatile than the S&P 500 by 101.152%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liquidia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics pays -- of its earnings as a dividend. Liquidia pays out -- of its earnings as a dividend.

United Therapeutics quarterly revenues are $794.4M, which are larger than Liquidia quarterly revenues of $3.1M. United Therapeutics's net income of $322.2M is higher than Liquidia's net income of -$38.4M. Notably, United Therapeutics's price-to-earnings ratio is 11.98x while Liquidia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 4.84x versus 80.84x for Liquidia. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 40.56% compared to United Therapeutics's net margin of -907.48%. United Therapeutics's return on equity of 19.92% beat Moderna's return on equity of -29.23%.

United Therapeutics has a consensus price target of $377.09, signalling upside risk potential of 25.63%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 41.47%. Given that Moderna has higher upside potential than United Therapeutics, analysts believe Moderna is more attractive than United Therapeutics.

United Therapeutics has a beta of 0.534, which suggesting that the stock is 46.629% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

United Therapeutics quarterly revenues are $794.4M, which are larger than Moderna quarterly revenues of $107M. United Therapeutics's net income of $322.2M is higher than Moderna's net income of -$971M. Notably, United Therapeutics's price-to-earnings ratio is 11.98x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 4.84x versus 4.17x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 40.56% compared to United Therapeutics's net margin of 23.33%. United Therapeutics's return on equity of 19.92% beat Vertex Pharmaceuticals's return on equity of -6.04%.

United Therapeutics has a consensus price target of $377.09, signalling upside risk potential of 25.63%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.23 which suggests that it could grow by 4.32%. Given that United Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe United Therapeutics is more attractive than Vertex Pharmaceuticals.

United Therapeutics has a beta of 0.534, which suggesting that the stock is 46.629% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.044%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

United Therapeutics quarterly revenues are $794.4M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. United Therapeutics's net income of $322.2M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, United Therapeutics's price-to-earnings ratio is 11.98x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 4.84x versus 11.19x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.